Can platelet count alone predict bleeding in patients with thrombocytopenia?

Marwa Zanaty Elsayed¹, Hamdy S Mohammed¹, Eman H Salama², Lotfy Hamed Abo-Dahab¹.

1- internal medicine department, Faculty of Medicine, Sohag University
2- clinical pathology department, Faculty of Medicine, Sohag University

Abstract:
The number of platelets is used to assess thrombopoiesis; it varies greatly between individuals, although it is relatively steady in healthy people, with a modest drop with age. The severity of thrombocytopenia is a considerable factor in determining bleeding risk. However, while some patients with platelet numbers less than 10,000 L⁻¹ have a little bleeding, others with platelet numbers above 50,000 L⁻¹ have large hemorrhages, indicating that platelet count alone may not necessarily predict the occurrence of bleeding in patients with a marked decrease in platelet number. Platelet function testing in thrombocytopenia may be useful as a diagnostic tool and as guidance to treatment for thrombocytopenic patients. Severe thrombocytopenia is a major risk factor for hemorrhage, but platelet function and bleeding risk at very low platelet counts are poorly understood due to the limitations of platelet function testing at very low platelet count. Using flow cytometry is generally independent of platelet number and hence possible in blood from individuals with thrombocytopenia.

Keywords: Platelet count, platelet function, thrombocytopenia, bleeding.

Introduction:
Thrombocytopenia is the most prevalent reason for hematologic consultation in medical practice, which is also one of the first most life-threatening illnesses. Platelets are important in the early stages of clot formation because they adhere to injured blood vessels and donate their membrane phospholipids to activate coagulation factors.

Degrees of thrombocytopenia
Thrombocytopenia is described as a platelet number that is less than the normal cutoff value, which in adults is 150,000/ microL. Mild thrombocytopenia (platelet count 100,000 to 150,000/microL), moderate thrombocytopenia (platelet count 50,000 to 99,000/ microL), and severe thrombocytopenia (platelet count 50,000/ microL). These numbers should be assessed according to the etiology, lower or higher levels may be acceptable in some circumstances. For example, in the setting of immune thrombocytopenia [ITP], we consider a platelet count of 30,000 as severe thrombocytopenia. The hazard of spontaneous mucocutaneous bleeding and potentially fatal spontaneous cerebral hemorrhage or gastrointestinal bleeding rises rapidly below 10 x 10⁹/L.

Causes of thrombocytopenia
It may be due to a decrease in platelet synthesis (hypo-productive) or acceleration in platelet consumption/destruction (hyper-destructive) thrombocytopenia. Hematological malignancies (leukemia, myeloma, myelodysplasia, and my-
elofibrosis), cytotoxic drugs or radiotherapy, infections (human immunodefi-
cency virus (HIV), Cytomegalovirus (CMV), hepatitis B, and C), aplastic and megaloblastic anemia, and
generalized bone marrow failures are all examples of hypo-productive thrombocyto-
penia (6).

Idiopathic/primary autoimmune (ITP), Secondary (systemic lupus erythematosus, chronic lymphocytic leukemia, lymphoma), Infections (HIV, hepatitis B, and C, malaria), Drug-induced (rifampicin, penicillin, sulphonamides, Heparin, quinine), and disseminated intravascular hemolysis (DIC) are all examples of hyper-destructive thrombocyto-
penia (1).

Platelet dysfunction may be a cause of bleeding in thrombocytopenic patients
Platelet bleeding disorders are a diverse group in terms of frequency and
bleeding severity; they are characterized by qualitative/function and/or quantitative/number platelet defects; However, when moderate (50–100*10^9
platelets/L) or even mild thrombocyto-
penia (>100–150 *10^9 platelets/L) is combined with hereditary or acquired defect in platelet function, bleeding owing to substantial hemostatic
problems, such as operations and injury, is very common (7, 8).

Although serious bleeding is more frequent when platelet numbers are below
10,000 L^{-1}, considerable hemorrhage can occur at higher platelet counts as well, the vast majority of individuals with even severe thrombocytopenia do not complain of spontaneous bleeding because of the presence of another cause of bleeding other than thrombocyto-
penia. (9, 10).

As a result, while severe thrombocyto-
penia cause bleeding, it is not ade-
quate. In a study of patients with hematologic malignancies who were
having stem cell transplantation or che-
motherapy, bleeding of World Health Organization grade 2 or above occurred at rates of 25% at platelet counts of 5000 L^{-1} and 17% at platelet levels of (20–80000 L^{-1}) (10).

Although 75 percent of intracranial hemorrhages (ICHs) resulted at platelet counts 10000 L^{-1}, 10% of ICHs occurred at platelet counts > 20000 L^{-1} (9) external events such as trauma or infection, as well as differences in platelet function, may lead to variations in bleeding risk among patients with nearly equivalent degrees of thrombocyto-
penia. Furthermore, because the types of bleeding differ, a better understanding of platelet function in thrombocyte-
penia could be a significant aspect that determines the risk of bleeding and, if so, could lead to better clinical manage-
ment (11).

Whereas bleeding is common in hematological cancers with bone marrow failure (12), bleeding is assumed to be fewer in thrombocytopenic conditions of increased platelet turnover, such as thrombocytopenic purpura (TTP), heparin-induced thrombocyto-
enia, and immune thrombocyto-
penia (ITP). In these conditions, the platelet number decreases due to depletion of platelet due to increased coagulation processes; and transfusion of platelet may lead to the occurrence of thrombosis and fatality (13).

marked thrombocytopenia is a sub-
stantial risk factor for bleeding, how-
ever, assessment of the relation between the possibility of occurrence of bleeding and the presence of defects in platelet function in thrombocytopenic patients remain unclear due to the difficulties in the platelet function measurements in severe thrombocytopenia (8).

The use of Flow cytometry in the assessment of platelet function: -
Flow cytometry represents the standard technique to quantify receptors and distinct platelet activation markers on the surface of platelets in citrated whole blood for the evaluation of quantitative receptor defects and increased platelet activation status in vivo, including the shedding of surface membrane receptors. The in vitro assessment of platelet reactivity in response to a variety of agonists, especially in low amounts of whole blood, demonstrates further strengths (14).

Platelet function assay relies on single-cell analysis using flow cytometry is generally independent of platelet number and hence possible in blood from individuals with thrombocytopenia. However, based on a new study, when platelet number $10^8$ $10^9$/mL may affect in vitro platelet activation tests because of platelet count-related decreased release of ADP, which serves as an important amplifier of platelet activation (15).

References: